News
Catch up with the latest happenings at Terremoto.
Catch up with the latest happenings at Terremoto.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Terremoto Biosciences Closes $175 Million Series B Financing
/in 2023, Press Release/by Emily HennesTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
/in 2022, Press Release/by eallisonTerremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.